Immunome is seeking a Senior Director, U.S. Market Development to lead and provide strategic direction for commercial market development activities in preparation for the potential launch of varegacestat in desmoid tumors. This role will be responsible for shaping the U.S. commercial and clinical landscape ahead of launch by building strategic relationships with key opinion leaders (KOLs), generating actionable market insights, and translating those insights into launch strategy. The Senior Director will ensure the U.S. market is informed, aligned, and ready for varegacestat at approval.
As a senior member of the U.S. Commercial organization, this individual will partner cross-functionally with Sales, Marketing, Market Access, Medical Affairs, Clinical Development, and HEOR to ensure launch plans are grounded in real-world insights and reflect the evolving treatment paradigm in desmoid tumors. The mission of this role is to help position varegacestat for strong adoption by establishing Immunome as a trusted commercial and scientific partner within the U.S. desmoid tumor community.
Responsibilities
U.S. Market Development & Launch Readiness
U.S. KOL Strategy & Commercial Engagement
Insight Generation & Competitive Intelligence
Congress Strategy & External Presence
Cross-Functional Collaboration
Qualifications
Knowledge and Skills
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.